Photocure Appoints Jane Healy to Lead European Expansion in Uro-Oncology

Photocure has appointed Jane Healy as General Manager, EMEA, to lead its European Organization at a pivotal time for the company. With over 30 years of experience in the medical device industry, including leadership roles at Boston Scientific, St. Jude Medical, and CR Bard, Healy brings a strong commercial acumen and strategic vision to drive Photocure’s expansion in uro-oncology. Most recently, she served as VP EMEA for Peripheral Interventions at Boston Scientific, where she played a key role in regional growth and market strategy. Fluent in four languages, she holds a BA (Hons) in Modern Languages from Cambridge University.

As Photocure reaffirms its leadership in bladder cancer diagnostics, Healy’s expertise will be crucial in advancing the adoption of Blue Light Cystoscopy (BLC) for precision diagnostics. Photocure’s European Organization was established after regaining Hexvix® sales and distribution rights from Ipsen Pharma in 2020, and the company has since gained strong momentum in the region. Dan Schneider, CEO of Photocure, expressed confidence in Healy’s ability to lead the next phase of growth, emphasizing her track record in building successful international teams. With significant innovation shaping the uro-oncology landscape, her leadership is expected to further strengthen Photocure’s impact on bladder cancer patient care.